Discontinued — last reported Q2 '25
Business Segments · Total revenues
U.S. Pharmaceutical — Total revenues
McKesson U.S. Pharmaceutical — Total revenues increased by 8.2% to $89.95B in Q2 2025 compared to the prior quarter. Year-over-year, this metric grew by 25.4%, from $71.72B to $89.95B. Over 3 years (FY 2022 to FY 2025), U.S. Pharmaceutical — Total revenues shows an upward trend with a 15.6% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityStable
First reportedQ2 2018
Last reportedQ2 2025
Rolls up toTotal Revenue
How to read this metric
Increasing revenue signals strong market demand and successful customer acquisition or price realization.
Detailed definition
The total gross sales generated by the U.S. Pharmaceutical segment from the distribution of branded, generic, and specia...
Peer comparison
Directly comparable to revenue metrics of other major pharmaceutical wholesalers.
Metric ID:
mck_segment_u_s_pharmaceutical_total_revenuesHistorical Data
17 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $50.02B | $53.41B | $55.04B | $53.68B | $56.95B | $60.06B | $61.93B | $61.68B | $67.16B | $69.77B | $73.02B | $68.79B | $71.72B | $85.73B | $87.11B | $83.17B | $89.95B |
| QoQ Change | — | +6.8% | +3.1% | -2.5% | +6.1% | +5.5% | +3.1% | -0.4% | +8.9% | +3.9% | +4.7% | -5.8% | +4.3% | +19.5% | +1.6% | -4.5% | +8.2% |
| YoY Change | — | — | — | — | +13.9% | +12.4% | +12.5% | +14.9% | +17.9% | +16.2% | +17.9% | +11.5% | +6.8% | +22.9% | +19.3% | +20.9% | +25.4% |
Range$50.02B – $89.95B
CAGR+15.8%
Avg YoY Growth+16.3%
Median YoY Growth+16.2%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is McKesson's u.s. pharmaceutical — total revenues?
- McKesson (MCK) reported u.s. pharmaceutical — total revenues of $89.95B in Q2 2025.
- How has McKesson's u.s. pharmaceutical — total revenues changed year-over-year?
- McKesson's u.s. pharmaceutical — total revenues increased by 25.4% year-over-year, from $71.72B to $89.95B.
- What is the long-term trend for McKesson's u.s. pharmaceutical — total revenues?
- Over 3 years (2022 to 2025), McKesson's u.s. pharmaceutical — total revenues has grown at a 15.6% compound annual growth rate (CAGR), from $212.15B to $327.72B.
- What does u.s. pharmaceutical — total revenues mean?
- Total sales revenue generated by the U.S. Pharmaceutical distribution business.